1. Metabolic Enzyme/Protease
  2. FXR

Sevelamer hydrochloride 

Cat. No.: HY-13995A Purity: 98.00%
Data Sheet SDS Handling Instructions

Sevelamer Hcl is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

For research use only. We do not sell to patients.
Sevelamer hydrochloride Chemical Structure

Sevelamer hydrochloride Chemical Structure

CAS No. : 152751-57-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $83 In-stock
100 mg $75 In-stock
500 mg $270 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Sevelamer hydrochloride:

Featured Recommendations

Related Screening Libraries:

  • Biological Activity

  • Technical Information

  • Purity & Documentation

  • References

Description

Sevelamer Hcl is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01543958 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infection November 2011 Phase 2
NCT01238588 Brigham and Women's Hospital Dialysis|Cardiovascular Disease|Atherosclerosis|Inflammation|Hyperphosphatemia June 10, 2011
NCT00833768 Genzyme, a Sanofi Company|Sanofi Chronic Kidney Disease|Hyperphosphatemia January 2009 Phase 3
NCT01191762 Kenneth R. Phelps, M.D.|Genzyme, a Sanofi Company|Phelps, Kenneth R., M.D. Hyperparathyroidism|Chronic Kidney Disease April 2010 Phase 3
NCT00745589 The University of Hong Kong Endstage Renal Disease July 2008
NCT00268957 Genzyme, a Sanofi Company|Sanofi Kidney Diseases|Chronic Renal Insufficiency|End-Stage Renal Disease January 2006 Phase 3
NCT01135615 Gulhane School of Medicine We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients. January 2008 Phase 4
NCT01574326 Genzyme, a Sanofi Company|Sanofi Hyperphosphatemia|Chronic Kidney Disease May 2012 Phase 2
NCT00267514 Genzyme, a Sanofi Company|Sanofi Chronic Kidney Disease January 2006 Phase 3
NCT01011699 Centre Hospitalier Universitaire, Amiens Chronic Renal Failure|Hemodialysis January 2010 Phase 3
NCT00837655 Karolinska Institutet|Göteborg University Kidney Failure, Chronic|End-Stage Renal Disease|Insulin Resistance|Hyperphosphatemia January 2009
NCT02332811 Genzyme, a Sanofi Company|Sanofi Renal Failure Chronic October 2013 Phase 3
NCT00681941 Genzyme, a Sanofi Company|Sanofi Chronic Kidney Disease|Hyperphosphatemia January 2006 Phase 3
NCT00806481 University Hospital Birmingham NHS Foundation Trust|Genzyme, a Sanofi Company Kidney Failure, Chronic|Cardiovascular Diseases February 2009 Phase 2
NCT01427907 Fresenius Medical Care North America Chronic Kidney Disease September 2011 Phase 4
NCT01220843 Centre Hospitalier Universitaire, Amiens|Genzyme, a Sanofi Company Chronic Renal Failure October 2010 Phase 3
NCT00967629 Icahn School of Medicine at Mount Sinai Diabetic Nephropathy June 2009 Phase 1
NCT01736150 Genzyme, a Sanofi Company|Sanofi Chronic Kidney Disease|Chronic Kidney Disease on Hemodialysis March 2010 Phase 3
NCT01755078 Chugai Pharma Taiwan Hemodialysis|Hyperphosphatemia|Cardiovascular Events June 2007 Phase 4
NCT01968759 Mario Negri Institute for Pharmacological Research Chronic Kidney Disease October 2013 Phase 2
NCT00853242 Genzyme, a Sanofi Company|Sanofi Kidney Failure, Chronic February 2009 Phase 2
NCT00364000 Romanian Society of Nephrology Haemodialyzed Patients|Hyperphosphatemia January 2012
NCT00756860 Amgen Research (Munich) GmbH|Amgen Healthy Volunteers May 2008 Phase 1
NCT00690937 Genzyme, a Sanofi Company|Manipal Acunova Ltd.|Sanofi Hypercholesterolemia February 2008 Phase 2
NCT00196755 Genzyme, a Sanofi Company|Sanofi Peritoneal Dialysis|Chronic Kidney Disease December 2004 Phase 3
NCT00441545 Shire Chronic Kidney Disease, Stage 5 February 2007 Phase 3
NCT01493050 Gary Striker|Icahn School of Medicine at Mount Sinai Diabetic Nephropathy February 2012 Phase 2
NCT00211939 Nabi Biopharmaceuticals Calcinosis|Arteriosclerosis|Hyperparathyroidism, Secondary January 2005 Phase 4
NCT01049815 Tel-Aviv Sourasky Medical Center|Wolfson Medical Center|Genzyme, a Sanofi Company End Stage Renal Disease|Hemodialysis|Intimal Media Thickness February 2005
NCT00440648 Genzyme, a Sanofi Company|Sanofi Chronic Kidney Disease March 2005 Phase 2
NCT00844662 Ineos Healthcare Limited Chronic Kidney Failure July 2009 Phase 3
NCT00875017 Shire Kidney Failure, Chronic April 2009 Phase 1
NCT00324376 Genzyme, a Sanofi Company|Sanofi Chronic Kidney Disease March 2003 Phase 2
NCT03001011 Sanofi Hyperphosphatemia June 7, 2017 Phase 3
NCT01277497 Albany College of Pharmacy and Health Sciences|Albany Medical College|Genzyme, a Sanofi Company Chronic Kidney Disease January 2011 Phase 4
NCT00925704 Shire Healthy June 2009 Phase 1
NCT00486772 Gulhane School of Medicine Vascular Diseases Phase 4
NCT01857024 Genzyme, a Sanofi Company|Sanofi Hyperphosphataemia|Chronic Kidney Disease September 2010
NCT01057407 Astellas Pharma Inc Chronic Kidney Disease|Renal Dialysis|Renal Insufficiency January 2010 Phase 3
NCT02199444 Federico II University Chronic Kidney Disease Stage 3-5 June 2014 Phase 3
NCT00704483 Novartis Pharmaceuticals|Novartis Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy July 2008 Phase 2
NCT01308242 Penn State University|Genzyme, a Sanofi Company Chronic Kidney Disease March 2011
NCT02644486 Zhi-Hong Liu, M.D.|Nanjing University School of Medicine Obesity and Glomerulopathy January 2016
NCT03202407 Assiut University Hyperphosphatemia August 1, 2017 Phase 3
NCT00999037 University of California, Los Angeles|Loma Linda University Secondary Hyperparathyroidism October 2009
NCT01464190 Vifor Inc.|Fresenius Medical Care North America Chronic Kidney Disease Requiring Chronic Dialysis September 2011 Phase 3
NCT00704678 Novartis Pharmaceuticals|Novartis Chronic Kidney Disease August 2008 Phase 2
NCT00324571 Genzyme, a Sanofi Company|Sanofi Chronic Kidney Disease March 2001 Phase 4
NCT00710788 Azienda Sanitaria ASL Avellino 2 Cardiovascular Mortality January 2007
NCT02124759 The University of Texas Health Science Center at San Antonio|American Diabetes Association Insulin Sensitivity April 2014 Phase 2
NCT00542815 Mitsubishi Tanabe Pharma Corporation Chronic Kidney Disease|Dialysis|Hyperphosphatemia November 2007 Phase 3
NCT02127125 The University of Texas Health Science Center at San Antonio|American Diabetes Association Insulin Sensitivity April 2014 Phase 2
NCT02061124 University Hospital, Gentofte, Copenhagen|Sanofi Type 2 Diabetes February 2014
NCT01324128 Vifor Inc.|Fresenius Medical Care North America Chronic Kidney Disease Requiring Chronic Dialysis March 2011 Phase 3
NCT00785629 Denver Nephrologists, P.C.|Shire|Fresenius Medical Care North America|Genzyme, a Sanofi Company|Novartis Pharmaceuticals|DaVita Dialysis Chronic Kidney Disease February 2009
NCT00505037 Astellas Pharma Inc Hyperphosphatemia|Chronic Kidney Disease October 2007 Phase 2
NCT02445508 University Hospital, Gentofte, Copenhagen|Sanofi Diabetes Mellitus, Type 2 May 2015
NCT00436683 Ineos Healthcare Limited Chronic Kidney Failure February 2007 Phase 2
NCT01191255 Keryx Biopharmaceuticals Hyperphosphatemia|Kidney Failure October 2010 Phase 3
NCT01850602 Kissei Pharmaceutical Co., Ltd. Hemodialysis|Hyperphosphatemia Phase 3
NCT00560300 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Secondary Hyperparathyroidism|Renal Osteodystrophy November 2000 Phase 2
NCT02822131 University of Zurich Hypertension January 2016
NCT01057186 Haukeland University Hospital Hypophosphatemia, Familial|Rickets|Hyperphosphatemia December 2009
NCT00416520 Mitsubishi Tanabe Pharma Corporation Chronic Kidney Disease|Hyperphosphatemia June 2007 Phase 3
NCT00018135 National Center for Research Resources (NCRR) Renal Failure
NCT00824460 Vifor Inc. Chronic Kidney Disease December 2008 Phase 2
View MoreCollapse
References
Molecular Weight

186.08 (monomer)

Formula

(C₃H₇N . C₃H₅ClO)x . x HCl

CAS No.

152751-57-0

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 98.00%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sevelamer hydrochloride
Cat. No.:
HY-13995A
Quantity: